Among them, three trials are designed to evaluate CD44v6‐specific CAR T‐cell therapies; two trials are using humanized mAb drugs for the treatment of CD44+ cancer; two trials are aimed at inhibiting the expression of CD44 in cancer; and one trial is about a drug designed to bind to CD44 for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. This evidence concerns the gene CD44 and B-cell chronic lymphocytic leukemia.